Level C· Early human research exploring benefitsProspective StudyPubMed

Inducing Neural Fate: The Impact of Phenylacetate and Calcium on Human Adipose-derived Mesenchymal Stem Cells Differentiation.

Ghiasi M., Hajipur M., Ghollasi M., Dayani A., Moradi MT., Salimi A.

Prospective Study on Neuroinflammation, published in Curr Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Curr Stem Cell Res Ther (2025)
Country
United Arab Emirates
Reported sample size
—
Source database
PubMed
PMID
39679461
DOI
10.2174/011574888X355333241203114713
Citations
3

Abstract (original English)

Introduction Human adipose-derived stem cells (hADSCs) are considered a promising source for cell replacement therapy in degenerative and traumatic conditions. This study explores the effects of phenylacetate and calcium on the neural differentiation of hADSCs for regenerative medicine. We assessed cell viability and cytotoxicity using the MTT assay, revealing that treatment with 1μM phenylacetate significantly enhanced cell viability compared to control groups over five days, while higher concentrations resulted in cytotoxic effects. Method Additionally, qualitative analysis through Acridine orange/ethidium bromide (AO/EB) staining indicated normal cellular characteristics at lower phenylacetate concentrations, whereas higher doses led to observable cell death. A subsequent evaluation of intracellular calcium levels demonstrated a significant increase when hADSCs were treated with both phenylacetate and calcium. Results The neural differentiation potential was further assessed through the relative quantification of neuronal-specific genes, showing marked upregulation of NSE, Oligo-2, β-tubulin III , and MAP-2 in all treatment groups compared to controls. Immunohistochemistry confirmed elevated protein expression of neural markers in cultures supplemented with phenylacetate and calcium. Conclusion These findings suggest that phenylacetate, particularly in conjunction with calci

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansPhenylacetatesMesenchymal Stem CellsCell DifferentiationCalciumAdipose TissueCell SurvivalNeuronsCells, Cultured

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research